The New England Journal of Medicine4d
Nivolumab plus Ipilimumab in Advanced Melanoma
To the Editor: In the final, 10-year outcomes of the CheckMate 067 trial reported by Wolchok et al. (Jan. 2 issue), 1 the combination of nivolumab and ipilimumab resulted in an unprecedented ...
Bristol Myers Squibb Receives Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo® (nivolumab) Across Multiple Solid Tumor Indications
Bristol Myers Squibb Receives Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo® (nivolumab) Across Multiple Solid Tumor Indications ...
Hosted on MSN26d
Adjuvant Nivolumab Boosts Survival Outcomes in Muscle-Invasive Bladder Cancer
SAN FRANCISCO -- Post-surgical adjuvant nivolumab (Opdivo) improved survival outcomes in muscle-invasive bladder cancer (MIBC), regardless of the use of neoadjuvant chemotherapy, according to ...
Finanznachrichten2d
Bristol Myers Squibb Receives Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo (nivolumab) Across Multiple Solid Tumor Indications
Recommendation is based primarily on results from the Phase 3 CheckMate -67T trial which demonstrated noninferiority in the co-primary endpoints of C avgd28 and C minss and consistent efficacy in ...